Niepubliczny Zaklad Opieki Zdrowotnej Twoja Przychodnia Sp. z o.o.

Research site

Poland Ul. Krola Rogera 6, 20-857 Lublin, Poland

2 trials recruiting
Arteriosclerosis · Heart failure with reduced ejection fraction · Atrial fibrillation
Adult patients

About Specializations

Niepubliczny Zaklad Opieki Zdrowotnej Twoja Przychodnia Sp. z o.o. in Lublin, Poland specialises in clinical trials of conditions such as Arteriosclerosis, Heart failure with reduced ejection fraction, Atrial fibrillation, Cardiac failure, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

The cardiology department at Niepubliczny Zaklad Opieki Zdrowotnej Twoja Przychodnia focuses on cardiovascular diseases. Researchers are studying atherosclerotic cardiovascular disease with elevated lipoprotein(a), chronic heart failure with reduced ejection fraction, and atrial fibrillation‑related stroke risk. The trials evaluate new treatments designed to lower heart‑failure hospitalizations, improve stroke prevention, and reduce major cardiac events.

Vericiguat in chronic heart failure with reduced ejection fraction
Asundexian versus apixaban for stroke prevention in atrial fibrillation
Olpasiran targeting lipoprotein(a) to reduce coronary events

Located in Lublin, Poland, the clinic collaborates with two investigators to advance cardiovascular care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Ul. Krola Rogera 620-857 LublinPoland

Open in maps ↗

Recruiting now: 2 trials
Conditions studied: 11

More sites in Lublin Poland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

9 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Poland

Participants:18–64 years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S

Contact Research Centre

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Recruiting

Registered drug

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Baxdrostat
Sponsor:AstraZeneca AB

Contact Research Centre

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational

Poland

Participants:18–64 years · 65+ years
Sponsor:Amgen Inc.

Contact Research Centre

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Evolocumab
Sponsor:Amgen Inc.

Contact Research Centre

Cardiac failure chronic+1

Not recruiting

Study on the Safety of Starting Vericiguat at 5 mg in Patients with Chronic Heart Failure with Reduced Ejection Fraction

InvestigationalNo placebo

Study on the Safety of Starting Vericiguat at 5 mg in Patients with Chronic Heart Failure with Reduced Ejection Fraction

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Vericiguat
Sponsor:Bayer AG

Contact Research Centre

Type IIa hyperlipidaemia

Not recruiting

Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

Investigational

Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

Investigational

Poland

Participants:18–64 years · 65+ years
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Cardiac failure

Not recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Balcinrenone
Sponsor:AstraZeneca AB

Contact Research Centre

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Bayer AG

Contact Research Centre

Heart failure with reduced ejection fraction

Not recruiting

Study on Vericiguat for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational

Study on Vericiguat for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Vericiguat
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites